Peter Foley

Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry

Brent J Doolan, Digsu Koye, Joanna Ling, Geoffrey D Cains, Christopher Baker, Peter Foley, Con Dolianitis

Journal article  |  2020  |  Australasian Journal of Dermatology

BACKGROUND: Psoriasis is a chronic inflammatory disease affecting ~2-3% of the Australasian population. Therapeutic options includ..

Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative

Marius Rademaker, Katherine Armour, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Gillian Marshman, Alicia O'Connor, Diana Rubel, John Sullivan, Li-Chuen Wong

Journal article  |  2020  |  Australasian Journal of Dermatology

Chronic hand/foot eczemas are common, but treatment is often challenging, with widespread dissatisfaction over current available o..

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement

Charlie Wang, Marius Rademaker, Christopher Baker, Peter Foley

Journal article  |  2020  |  Australasian Journal of Dermatology

Beyond skin deep: addressing comorbidities in psoriasis.

Tom Kovitwanichkanont, Alvin H Chong, Peter Foley

Journal article  |  2020  |  Medical Journal of Australia

Psoriasis is a chronic inflammatory disease that is commonly encountered in primary care and is associated with significant morbid..

Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry

William Berry, Benjamin S Daniel, Christopher Baker, Peter Foley

Journal article  |  2020  |  Australasian Journal of Dermatology

Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.

B Strober, A Menter, C Leonardi, K Gordon, J Lambert, L Puig, H Photowala, M Longcore, T Zhan, P Foley

Journal article  |  2020  |  Journal of the European Academy of Dermatology and Venereology

BACKGROUND: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin-23 through binding the p19 s..

Infliximab drug survival in chronic plaque psoriasis: follow-up of the product familiarisation program

William Berry, Benjamin Daniel, Rebecca Nguyen, Chris Baker, Peter Foley

Journal article  |  2020  |  Australasian Journal of Dermatology

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Lynda Spelman, Diana Rubel, Alan Brnabic, Nicole Burkhardt, Elisabeth Riedl, Peter Foley

Journal article  |  2020  |  Journal of Dermatological Treatment

Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases

Marius Rademaker, Christopher Baker, Peter Foley, John Sullivan, Charlie Wang

Journal article  |  2020  |  Australasian Journal of Dermatology

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher EM Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Chenglong Han, Alexa B Kimball, April W Armstrong, Peter Foley, Andrew Blauvelt

Journal article  |  2020  |  Journal of the American Academy of Dermatology

BACKGROUND: Long-term maintenance treatment is required for patients with psoriasis. OBJECTIVES: To evaluate the efficacy and safe..